Novo Nordisk (NOVOB DC) sues Eli lilly (LLY) in US federal court, alleging claim under the Lanham Act, according to court records

Novo Nordisk's lawsuit against Eli Lilly under the Lanham Act suggests it perceives a competitive threat from misleading advertising claims related to weight loss products.

Newsquawk StaffPublished On the live feed at 4 more headlines followed before this page went public
Newsquawk headlinesUTC

European Commission will impose its first fine under the DMA on Thursday against Google (GOOGL), fine of up to ten percent of global annual revenue is possible, reports Handelsblatt

Tesco (TSCO LN) announces new partnerships with Uber Eats (UBER), launching in August, and Deliveroo (DASH), which will roll out later this summer

Novo Nordisk (NOVOB DC) sues Eli lilly (LLY) in US federal court, alleging claim under the Lanham Act, according to court records

Charles Schwab (SCHW) Q2 2026 (USD): EPS 1.62 (exp. 1.56), Revenue 7.07bln (exp. 6.90bln)

US PRE-MARKET MOVERS: TSM, NBIS, CCK, DHR, HAS, GM, MMM

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
  • Is suing over misleading weight loss ads. 
Context

The market may view this as a significant strategic move that could shape consumer perception and competitive dynamics in the pharmaceutical sector, particularly affecting stock performance in both companies and potentially influencing broader sector sentiment.

Related headlines

The whole workspace, free to try.

Try it free